ced pexels 16677968

Cannabinoid Clinical Trials: Cannabis Anxiety Relief Study

Clinical Takeaway

Cannabis flower and edible products differ in how they affect anxiety on a daily and long-term basis, with product type and cannabinoid composition playing meaningful roles in outcomes. THC and CBD appear to have distinct and sometimes opposing influences on anxiety, making product selection clinically relevant for patients using cannabis to manage anxiety symptoms.

Cannabinoid Clinical Trials: Cannabis Anxiety Relief Study

#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.

Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.

Study type: Journal Article, Randomized Controlled Trial  |  Topic area: Cannabidiol  |  CED Score: 11

Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2

Quality Gate Alerts:

  • Preclinical only

Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.

 |   | 

View on PubMed ↗Full Text ↗DOI ↗